Target- |
MechanismCytotoxic T lymphocytes stimulants [+2] |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
HRYZ-T101 治疗 HPV18 阳性恶性实体瘤的Ⅰ期开放临床研究
[Translation] Phase I open-label clinical study of HRYZ-T101 in the treatment of HPV18-positive malignant solid tumors
主要目的:评价HRYZ-T101注射液治疗既往经标准治疗失败的复发或转移性、且HPV18阳性实体瘤患者的安全性和耐受性,并确定II期临床试验的推荐给药剂量(RP2D)。次要目的:(1)初步探索HRYZ-T101注射液治疗既往经标准治疗失败的复发或转移性、且HPV18阳性实体瘤患者的临床有效性;(2)评价HRYZ-T101注射液给药后,TCR-T细胞在受试者体内活化、扩增及存续情况;(3)评价HRYZ-T101注射液给药后外周血细胞因子水平及炎性标志物变化。
[Translation] Main purpose: To evaluate the safety and tolerability of HRYZ-T101 injection in the treatment of patients with recurrent or metastatic HPV18-positive solid tumors who have failed standard treatments, and to determine the recommended dosage (RP2D) for phase II clinical trials. Secondary purposes: (1) Preliminarily explore the clinical effectiveness of HRYZ-T101 injection in the treatment of patients with recurrent or metastatic HPV18-positive solid tumors who have failed standard treatment in the past; (2) Evaluate the effectiveness of HRYZ-T101 injection after administration of HRYZ-T101 injection. The activation, expansion and persistence of TCR-T cells in subjects; (3) Evaluate the changes in peripheral blood cytokine levels and inflammatory markers after administration of HRYZ-T101 injection.
A Multicenter, Single Arm, Open Label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of HRYZ-T101 Injection for HPV18 Positive Solid Tumor
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.
100 Clinical Results associated with HRYZ (Shanghai) Biotech Co., Ltd.
0 Patents (Medical) associated with HRYZ (Shanghai) Biotech Co., Ltd.
100 Deals associated with HRYZ (Shanghai) Biotech Co., Ltd.
100 Translational Medicine associated with HRYZ (Shanghai) Biotech Co., Ltd.